Basit öğe kaydını göster

dc.contributor.authorBadavath, Vishnu Nayak
dc.contributor.authorBaysal, Ipek
dc.contributor.authorUcar, Gulberk
dc.contributor.authorSinha, Barij Nayan
dc.contributor.authorJayaprakash, Venkatesan
dc.date.accessioned2019-12-16T10:29:29Z
dc.date.available2019-12-16T10:29:29Z
dc.date.issued2016
dc.identifier.issn1948-5875
dc.identifier.urihttps://doi.org/10.1021/acsmedchemlett.5b00326
dc.identifier.urihttp://hdl.handle.net/11655/20128
dc.description.abstractA series of new 2-methoxy-4-(5-pheny1-4,5dihydro-1H-pyrazol-3-yl)phenolderivatives, 4-13, were synthesized and tested for their human MAO inhibitory activity. All the compounds were found to be selective and reversible toward hMAO-A except 4, a selective inhibitor of hMAO-B and 12, a nonselective inhibitor. Compound 7 was found to be a potent inhibitor of hMAO-A with K-i = 0.06 +/- 0.003 mu M and was having selectivity index of (SI = 1.02 X 10(-5)). It was found to be better than standard drug, Moclobemide (hMAO-A with K = 0.11 +/- 0.01 mu M) with selectivity index of SI = 0.049. Molecular docking simulation was carried out to understand the crucial interactions responsible for selectivity and potency.
dc.language.isoen
dc.publisherAmer Chemical Soc
dc.relation.isversionof10.1021/acsmedchemlett.5b00326
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPharmacology & Pharmacy
dc.titleMonoamine Oxidase Inhibitory Activity Of Novel Pyrazoline Analogues: Curcumin Based Design And Synthesis
dc.typeinfo:eu-repo/semantics/article
dc.relation.journalAcs Medicinal Chemistry Letters
dc.contributor.departmentBiyokimya
dc.identifier.volume7
dc.identifier.issue1
dc.identifier.startpage56
dc.identifier.endpage61
dc.description.indexWoS


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster